At Inorevia, we believe that the next step in laboratory automation is miniaturization through microfluidics. By using a unique and patented combination of microfluidics and magnetic particles, our technology enables the automation of high througput, low volumes biological analyses for biology and medicine.
The technologies developped by Inorevia manipulates nanoliter volumes, drastically reducing reagents and samples consumptions.
Parallelization and complete automation accelerate complex biology protocols and reduce downtimes.
Computer-assisted flow control and contamination-free technology ensure robustness and reproducibility of your results.
Our protocol-agnostic technology is compatible with a wide range of applications in biology and medicine.
Inorevia's technology stems from 15 years
of research led at the Institute Curie (UMR168, CNRS).
Inorevia continues to receive strong
national and regional support, particularly from the Ile de France
region.
Inorevia received a 2M€ grant from the European Comission to apply it's core technology to sample preparation for Next-Generation Sequencing. More details here: https://cordis.europa.eu/project/rcn/224761/factsheet/en
Inorevia received a grant from "Région Ile de France" for an ambitious project in microfluidics.
Inorevia is proud to be amongst the winners of the 2018 Headstart Funding Programme by EIT Health, to promote game-changing technology in healthcare. More information here.
Inorevia is a spin-off from the Institut Curie, leveraging several patented technologies developped by a world renowed team of researchers in the field of microfluidics.
contact@inorevia.com
27 rue du Faubourg Saint-Jacques
75014, Paris
FRANCE
